J A Keiser
Overview
Explore the profile of J A Keiser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perrin L, June J, Rosebury W, Robertson A, Kovesdi I, Bruder J, et al.
Gene Ther
. 2004 Mar;
11(6):512-21.
PMID: 14999223
Adenovirus-mediated VEGF gene delivery is being evaluated in clinical trials as a treatment for patients with vascular diseases that stem from ischemia, such as diffuse coronary artery disease and peripheral...
2.
Wang H, Gordon D, OLSZEWSKI B, Song Y, Kovesdi I, Keiser J
Int J Mol Med
. 2000 Nov;
6(6):645-53.
PMID: 11078823
Therapeutic angiogenesis, either by protein injection or gene therapy, holds considerable promise for the treatment of coronary and peripheral artery diseases. Given the large number of angiogenic genes available, a...
3.
Wang H, Keiser J
Biochem Biophys Res Commun
. 2000 Jun;
272(3):900-5.
PMID: 10860849
Scatter factor (SF) or hepatocyte growth factor (HGF) has been identified as an angiogenic factor. Angiogenesis requires not only tube formation but also invasion of pericytes and extracellular matrix (ECM)...
4.
Kornowski R, Leon M, Fuchs S, Vodovotz Y, Flynn M, Gordon D, et al.
J Am Coll Cardiol
. 2000 Mar;
35(4):1031-9.
PMID: 10732905
Objectives: To test the feasibility of myocardial angiogenic gene expression using a novel catheter-based transendocardial injection system. Background: Angiogenesis has been induced by direct injection of growth factors into ischemic...
5.
Flynn M, Vodovotz Y, Kornowski R, Epstein S, Gordon D, Keiser J
Biotechniques
. 2000 Mar;
28(3):470-2, 475-6.
PMID: 10723559
The potential for using gene therapy to treat a variety of disease states is growing rapidly. Many vector types and delivery systems have been developed that allow the optimization of...
6.
Patt W, Cheng X, Repine J, Lee C, Reisdorph B, Massa M, et al.
J Med Chem
. 1999 Jun;
42(12):2162-8.
PMID: 10377221
Continued development around our ETA-selective endothelin (ET) antagonist 1 (CI-1020) has led to the synthesis of analogues with improved aqueous solubility profiles. Poor solubility characteristics displayed by 1 required a...
7.
Schroeder R, Keiser J, Cheng X, Haleen S
J Cardiovasc Pharmacol
. 1998 Dec;
32(6):935-43.
PMID: 9869499
The purpose of this study was to determine whether vascular endothelial and vascular smooth-muscle endothelin ET(B) receptors could be quantitatively differentiated by PD 142893 (PD), SB 209670 (SB), and BQ...
8.
Wang H, Keiser J
Circ Res
. 1998 Oct;
83(8):832-40.
PMID: 9776730
Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis that stimulates proliferation, migration, and proteolytic activity of endothelial cells. Although the mitogenic activity of VEGF is endothelial cell...
9.
Rekhter M, Hicks G, Brammer D, Work C, Kim J, Gordon D, et al.
Circ Res
. 1998 Oct;
83(7):705-13.
PMID: 9758640
Atherosclerotic plaque rupture is the main cause of coronary thrombosis and myocardial infarcts. Currently, there is no animal model of plaque disruption. We have developed a rabbit model in which...
10.
Ryan M, Emig L, Hicks G, Ramharack R, Brammer D, Gordon D, et al.
Atherosclerosis
. 1998 Aug;
139(1):137-45.
PMID: 9699901
Lipoprotein(a) [Lp(a)] has been proposed as a risk factor for both restenosis and coronary heart disease. Recently, we identified Lp(a) in the arterial wall during the initial rapid neointimal growth...